Pharmacometrics 2020

Journal of Clinical Pharmacology

Volumn 50, Issue 9, 2010, Pages

  Gobburu, Jogarao V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Clinical pharmacology; clinical trials; pharmaceutical research and development; pharmacodynamics.; regulatory; scientific affairs

Indexed keywords

ETANERCEPT; GABAPENTIN; KETOROLAC; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXCARBAZEPINE; REMIFENTANIL;

CLINICAL RESEARCH; COST CONTROL; DECISION MAKING; DRUG APPROVAL; DRUG LABELING; DRUG RESEARCH; HUMAN; MODEL; PHARMACOMETRICS; QUANTITATIVE ANALYSIS; REVIEW; RISK BENEFIT ANALYSIS; SIMULATION; STANDARDIZATION;

CLINICAL TRIALS AS TOPIC; DECISION MAKING, ORGANIZATIONAL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN;

EID: 78449266624     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010376977     Document Type: Review

References (33)

1. Wagner JG History of pharmacokinetics. Pharmacol Ther. 1981 ; 12: 537-562.
2. Nagashima R., O'Reilly RA, Levy G. Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther. 1969 ; 10: 22-35.
3. Sheiner LB, Stanski DR, Vozeh S., Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979 ; 25: 358-371.
4. Holford NH, Sheiner LB Kinetics of pharmacologic response. Pharmacol Ther. 1982 ; 16: 143-166.
5. Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther. 1992 ; 51: 465-473.
6. Sheiner LB, Beal SL, Rosenberg B., Marathe VV Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979 ; 26: 294-305.
7. Peck CC, Barrett BB Nonlinear least-squares regression programs for microcomputers. J Pharmacokinet Biopharm. 1979 ; 7: 537-541.
8. Weiner DL NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol. 1986 ; 8: 625-628.
9. Chan PLS, Holford NHG. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001 ; 41: 625-659.
10. Gobburu JV, Lesko LJ Quantitative disease, drug, and trial models. Ann Rev Pharmacol Toxicol. 2008 ; 49: 291-301.
11. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care. 2003 ; 26: 3093-3101.
12. Bangs A. Predictive biosimulation and virtual patients in pharmaceutical R and D. Stud Health Technol Inform. 2005 ; 111: 37-42.
13. Landersdorfer CB, Jusko WJ Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet. 2008 ; 47: 417-448.
14. Danhof M., de Jongh J., De Lange EC, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007 ; 47: 357-400.
15. Dobin RE Regulation of the medical use of psychedelics and marijuana. Doctoral dissertation, Harvard University. http://www.maps.org/dissertation/ dissertation.pdf. 2000: 168-169. Accessed June 1, 2010.
16. Egan TD, Muir KT, Hermann DJ, Stanski DR, Shafer SL The electroencephalogram (EEG) and clinical measures of opioid potency: defining the EEG-clinical potency relationship ("fingerprint") with application to remifentanil. Int J Pharm Med. 2001 ; 15: 11-19.
17. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C., van BP An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development: experience within Hoffmann La Roche. Clin Pharmacokinet. 1997 ; 33: 142-152.
18. Olson SC, Bockbrader H., Boyd RA, et al. Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis. Clin Pharmacokinet. 2000 ; 38: 449-459.
19. Zhang L., Sinha V., Forgue ST, et al. Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn. 2006 ; 33: 369-393.
20. Lalonde RL, Kowalski KG, Hutmacher MM, et al. Model-based drug development. Clin Pharmacol Ther. 2007 ; 82: 21-32.
21. Lee H., Yim DS, Zhou H., Peck CC Evidence of effectiveness: how much can we extrapolate from existing studies ? AAPS J. 2005 ; 7: E467 - E474.
22. Bhattaram VA, Booth BP, Ramchandani RP, et al. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications. AAPS J. 2005 ; 7: E503 - E512.
23. Li F., Nandy P., Chien S., Noel GJ, Tornoe CW Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob Agents Chemother. 2010 ; 54: 375-379.
24. Stone J., Banefield C., Pfister M., et al. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacol. 2010 ; 50 (suppl 1). 20S - 30S.
25. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenoalte mofetil in renal transplant. Clin Pharmacol Ther. 1998 ; 64: 672-683.
26. Wang Y., Bhattaram AV, Jadhav PR, et al. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. J Clin Pharmacol. 2008 ; 48: 146-156.
27. Firmagon's approval history. www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=search.Label- ApprovalHistory. Accessed May 21, 2010.
28. Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm167032.htm. Accessed June 1, 2010.
29. Wetherington J., Pfister M., Banefield C., et al. Model-based drug development: strengths, weaknesses, opportunities and threats for broad implementation in drug development. J Clin Pharmacol. 2010 ; 50 (suppl 1). 31S - 46S.
30. Tornoe CW, Garnett CE, Wang Y., Florian J., Li M., Gobburu JVS. Creation of a knowledge management system for QT analyses. J Clin Pharmacol. (in press).
31. Romero K., Corrigan B., Tornoe C., et al. Pharmacometrics as a discipline is entering the "industrialization" phase: standards, automation, knowledge sharing and training are critical for future success. J Clin Pharmacol. 2010 ; 50 (suppl 1). 20S - 31S.
32. Jadhav P., Neal L., Florian J., et al. Antiviral Information Management System (AIMS): a prototype for operational innovation in drug development. J Clin Pharmacol. 2010 ; 50 (suppl 1). 50S - 55S.
33. http://www.nice.org.uk/aboutnice/scientificadvice/ AboutScientificAdvice. jsp. Accessed June 1, 2010.